CureVac’s COVID-19 Vaccine Produces Grade 3 Adverse Events
Biopharmaceutical company CureVac NV of Tübingen, Germany has released the interim results of its Phase 1 clinical trial on its experimental CVnCoV vaccine COVID-19. The vaccine, which was given to more than 250 healthy adults 18 to 60 years of age, is based on messenger ribonucleic acid (mRNA) technology.1 2 Unlike traditional vaccines, mRNA vaccines […]